Nearly every adult on Earth carries Epstein–Barr virus silently in their memory B cells — a latency that occasionally resurfaces as lymphoma, multiple sclerosis risk, or other autoimmune conditions. Understanding exactly how EBV establishes that lifelong foothold during initial infection has been technically difficult, because the early events unfold inside tonsillar tissue that is hard to model in the lab. A new platform may change that calculus.
Researchers developed a three-dimensional tonsil organoid system that recapitulates the microenvironment of germinal centers — the specialized lymphoid structures where B cells undergo rapid proliferation and antibody diversification. Using this model, they mapped distinct infected B cell states that emerge during primary EBV exposure, characterizing how the virus navigates the germinal center reaction to seed long-lived memory B cell reservoirs. The organoid preserved key cellular architecture, including follicular helper T cells and stromal support cells, enabling observation of virus-host dynamics that standard two-dimensional culture systems cannot replicate.
This work sits at an important intersection of virology and immunology. EBV's exploitation of the germinal center was hypothesized for decades — the "germinal center model" of EBV latency has been influential since the 1990s — but direct observation of the infected cell states during primary infection in a physiologically relevant system has remained elusive. The organoid approach builds on a broader wave of tissue-mimetic models that have transformed how researchers study pathogens without relying on rare primary tissue samples or imperfect animal analogues. The key limitation here is that organoids, however sophisticated, still lack a full adaptive immune circuit including circulating T and NK cell surveillance. That caveat matters because EBV pathogenesis is profoundly shaped by immune control. Nonetheless, identifying the specific B cell transcriptional states EBV exploits during early germinal center transit could eventually inform vaccine design or therapeutic strategies aimed at interrupting latency establishment — a goal with implications for EBV-associated cancers and potentially for MS prevention.